3篇
您的检索式：作者名="Tiewei Cheng"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 2018 Chinese Pediatric Cardiology Society(CPCS) guideline for diagnosis and treatment of syncope in children and adolescents显示文摘Syncope belongs to the transient loss of consciousness(TLOC), characterized by a rapid onset, short duration, and spontaneous complete recovery. It is common in children and adolescents, accounting for 1% to 2% of emergency department visits.Recurrent syncope can seriously affect children's physical and mental health, learning ability and quality of life and sometimes cardiac syncope even poses a risk of sudden death. The present guideline for the diagnosis and treatment of syncope in children and adolescents was developed for guiding a better clinical management of pediatric syncope. Based on the globally recent development and the evidence-based data in China, 2018 Chinese Pediatric Cardiology Society(CPCS) guideline for diagnosis and treatment of syncope in children and adolescents was jointly prepared by the Pediatric Cardiology Society, Chinese Pediatric Society, Chinese Medical Association(CMA)/Committee on Pediatric Syncope, Pediatricians Branch, Chinese Medical Doctor Association(CMDA)/Committee on Pediatric Cardiology, Chinese College of Cardiovascular Physicians, Chinese Medical Doctor Association(CMDA)/Pediatric Cardiology Society, Beijing Pediatric Society, Beijing Medical Association(BMA). The present guideline includes the underlying diseases of syncope in children and adolescents, the diagnostic procedures, methodology and clinical significance of standing test and headup tilt test, the clinical diagnosis vasovagal syncope, postural orthostatic tachycardia syndrome, orthostatic hypotension and orthostatic hypertension, and the treatment of syncope as well as follow-up. | Cheng Wang Yaqi Li Ying Liao Hong Tian Min Huang Xiangyu Dong Lin Shi Jinghui Sun Hongfang Jin Junbao Du Jindou An Jie Chen Mingwu Chen Qi Chen Sun Chen Yonghong Chen Zhi Chen Adolphus Kai-tung Chau Junbao Du Zhongdong Du Junkai Duan Hongyu Duan Xiangyu Dong Lin Feng Lijun Fu Fangqi Gong Yonghao Gui Ling Han Zhenhui Han Bing He Zhixu He Xiufen Hu Yimin Hua Guoying Huang Min Huang Ping Huang Yujuan Huang Hongfang Jin Mei Jin Bo Li Fen Li Tao Li Xiaohui Li Xiaoyan Liu Yan Li Haitao Lv Tiewei Lv Zipu Li Luyi Ma Silin Pan Yusheng Pang Hua Peng Yuming Qin Jie Shen Lin Shi Kun Sun Jinghui Sun Hong Tian Jie Tian Cheng Wang Hong Wang Lei Wang Jinju Wang Wendi Wang Yuli Wang Rongzhou Wu Tianhe Xia Yanyan Xiao Chunhong Xie Yanlin Xing Zhenyu Xiong Baoyuan Xu Yi Xu Hui Yan Shiwei Yang Qijian Yi Xia Yu Xianyi Yu Yue Yuan Hongyan Zhang Huili Zhang Li Zhang Qingyou Zhang Xi Zhang Yanmin Zhang Zhiwei Zhang Cuifen Zhao Bin Zhou Hua Zhu | 2018 | Science Bulletin2018，63，23： | 54 |
| 2 | Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy显示文摘 | Woonyoung Choi Sima Porten Seungchan Kim Daniel Willis Elizabeth R. Plimack Jean Hoffman-Censits Beat Roth Tiewei Cheng Mai Tran I-Ling Lee Jonathan Melquist Jolanta Bondaruk Tadeusz Majewski Shizhen Zhang Shanna Pretzsch Keith Baggerly Arlene Siefker-Rad | 2014 | Cancer Cell2014，，： | 1 |
| 3 | Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat显示文摘Aim:Multiple myeloma(MM)is a hematological malignancy of antibody-producing mature B cells or plasma cells.The proteasome inhibitor,bortezomib,was the first-in-class compound to be FDA approved for MM and is frequently utilized in induction therapy.However,bortezomib refractory disease is a major clinical concern,and the efficacy of the pan-histone deacetylase inhibitor(HDACi),panobinostat,in bortezomib refractory disease indicates that HDAC targeting is a viable strategy.Here,we utilized isogenic bortezomib resistant models to profile HDAC expression and define baseline and HDACi-induced expression patterns of individual HDAC family members in sensitive vs.resistant cells to better understanding the potential for targeting these enzymes.Methods:Gene expression of HDAC family members in two sets of isogenic bortezomib sensitive or resistant myeloma cell lines was examined.These cell lines were subsequently treated with HDAC inhibitors:panobinostat or vorinostat,and HDAC expression was evaluated.CRISPR/Cas9 knockdown and pharmacological inhibition of specific HDAC family members were conducted.Results:Interestingly,HDAC6 and HDAC7 were significantly upregulated and downregulated,respectively,in bortezomib-resistant cells.Panobinostat was effective at inducing cell death in these lines and modulated HDAC expression in cell lines and patient samples.Knockdown of HDAC7 inhibited cell growth while pharmacologically inhibiting HDAC6 augmented cell death by panobinostat.Conclusion:Our data revealed heterogeneous expression of individual HDACs in bortezomib sensitive vs.resistant isogenic cell lines and patient samples treated with panobinostat.Cumulatively our findings highlight distinct roles for HDAC6 and HDAC7 in regulating cell death in the context of bortezomib resistance. | Tiewei Cheng Kendall Kiser Leslie Grasse Lakesla Iles Geoffrey Bartholomeusz Felipe Samaniego Robert Z.Orlowski Joya Chandra | 2021 | Cancer Drug Resistance2021，4，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员